Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27 467 patients taking rivaroxaban
Sally Tamayo, W Frank Peacock, Manesh Patel, Nicholas Sicignano, Kathleen P Hopf, Larry E Fields, Troy Sarich, Shujian Wu, Daniel Yannicelli, Zhong Yuan, Sally Tamayo, W Frank Peacock, Manesh Patel, Nicholas Sicignano, Kathleen P Hopf, Larry E Fields, Troy Sarich, Shujian Wu, Daniel Yannicelli, Zhong Yuan
Abstract
Background: In nonvalvular atrial fibrillation (NVAF), rivaroxaban is used to prevent stroke and systemic embolism.
Objective: To evaluate major bleeding (MB) in NVAF patients treated with rivaroxaban in a real-world clinical setting.
Methods: From January 1, 2013, to March 31, 2014, US Department of Defense electronic health care records were queried to describe MB rates and demographics. Major bleeding was identified using a validated algorithm.
Results: Of 27 467 patients receiving rivaroxaban, 496 MB events occurred in 478 patients, an incidence of 2.86 per 100 person-years (95% confidence interval: 2.61-3.13). The MB patients were older, mean (SD) age of 78.4 (7.7) vs 75.7 (9.7) years, compared with non-MB patients. Patients with MB had higher rates of hypertension (95.6% vs 75.8%), coronary artery disease (64.2% vs 36.7%), heart failure (48.5% vs 23.7%), and renal disease (38.7% vs 16.7%). Of MB patients, 63.2% were taking 20 mg, 32.2% 15 mg, and 4.6% 10 mg of rivaroxaban. Four percent of MB patients took warfarin within the prior 30 days. Major bleeding was most commonly gastrointestinal (88.5%) or intracranial (7.5%). Although 46.7% of MB patients received a transfusion, none had sufficient evidence of receiving any type of clotting factor. Fourteen died during their MB hospitalization, yielding a fatal bleeding incidence rate of 0.08 per 100 person-years (95% confidence interval: 0.05-0.14). Mean age at death was 82.4 years.
Conclusions: In this large observational study, the MB rate was generally consistent with the registration trial results, and fatal bleeds were rare.
© 2015 The Authors. Clinical Cardiology published by Wiley Periodicals, Inc.
References
- Andrade J, Khairy P, Dobrev D, et al. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. Circ Res. 2014;114:1453–1468.
- Mant J, Edwards D. Stroke prevention in atrial fibrillation: putting the guidelines into practice. Drugs Aging. 2010;27:859–870.
- January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014;130:2071–2104.
- Granger CB, Alexander JH, McMurray JJ, et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;15;365:981–992.
- Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE‐LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation [published correction appears in N Engl J Med. 2010;363:1877]. N Engl J Med. 2009;361:1139–1151.
- Patel MR, Mahaffey KW, Garg J, et al; ROCKET‐AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–891.
- Turpie AG, Lassen MR, Erikkson BI, et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty: pooled analysis of four studies. Thromb Haemost. 2011;105:444–453.
- Goodman SG, Wojdyla DM, Piccini JP, et al; ROCKET‐AF Investigators. Factors associated with major bleeding events: insights from the Rivaroxaban Once‐Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET‐AF). J Am Coll Cardiol. 2014;63:891–900.
- US Census Bureau. Age and sex composition in the United States : 2011. . Updated November 28, 2012. Accessed May 19, 2014.
- Cunningham A, Stein CM, Chung CP, et al. An automated database case definition for serious bleeding related to oral anticoagulant use. Pharmacoepidemiol Drug Saf. 2011;20:560–566.
- Lamberts M, Gislason GH, Lip GY, et al. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study. Circulation. 2014;129:1577–1585.
- Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864–2870.
- Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor‐Based Approach: The Euro Heart Survey on Atrial Fibrillation. Chest. 2010;137:263–272.
- Piccini JP, Garg J, Patel MR, et al; ROCKET‐AF Investigators. Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET‐AF trial. Eur Heart J. 2014;35:1873–1880.
Source: PubMed